Today, Bedrocan produces five plant varieties for medicine development, patients and clinical use. Each product is standardised according to pharmaceutical standards with a defined active ingredient composition. This reproducible chemical profile allows doctors to monitor dosage and condition progress like they would with any other treatment.

Every stage of the manufacturing process is GMP-certified (good manufacturing practice). GMP is a requirement of the pharmaceutical industry and it ensures consistency in active ingredients.

Are you an Australian healthcare professional?

Bedrocan has produced a brochure to support decision making by Australian prescribers and pharmacists on the safe and effective use of Bedrocan cannabis flos administered by vaporization.

To download the brochure Prescribing Bedrocan, we request your full contact details. Your details will be used by Bedrocan for the purposes of identifying you as a health professional

Prescribing Cannabis Au 28 August 2017 150x150 1 150x150

Prescribing Bedrocan – Palliative care


THC 22% |  CBD <1.0%

Introduced in 2003, Bedrocan® is  the brand name for the cultivar Cannabis sativa L. ‘Afina’.

Cannabis sativa L. ‘Afina’ is the first cultivar developed and it features 22% THC, with a CBD-level below 1%. It’s the most widely used medicinal cannabis product and has been used in more research than other products.

Bedrocan® is available in flos form.

Terpene Profile – Bedrocan

Content in mg/gr


THC 13.5% | CBD <1.0%

Introduced in 2005, Bedrobinol® is the brand name for the cultivar Cannabis sativa L. ‘Ludina’.

Cannabis sativa L. ‘Ludina’ is bred in-house by Bedrocan. Its THC-level can be considered medium strength, standardised at 13,5%, with a CBD-level below 1 %.

Bedrobinol® is available in flos form.

Terpene Profile – Bedrobinol

Content in mg/gr


THC 6.3% | CBD 8%

Introduced in 2007, Bediol® is the brand name for the cultivar Cannabis sativa L. ‘Elida’.

Cannabis sativa L. ‘Elida’ is one of the first cannabis cultivars developed specifically to have a higher CBD content. The effects of CBD are distinctly different from THC.

Bediol® has a balanced ratio of THC 6.3% and CBD 8%. Because it is easily tolerated, physicians often prescribe Bediol® for patients who previously have not used cannabis as a medicine. The ‘Elida’ cultivar was bred in-house by Bedrocan, specifically to meet the needs of patients.

Bediol® is available in granular form.

Terpene Profile – Bediol

Content in mg/gr

Bedica ®

THC 14% | CBD <1.0%

Introduced in 2011, Bedica® is the brand name for the indica cultivar Cannabis sativa L. ‘Talea’.

Cannabis sativa L. ‘Talea’ was developed in response to mounting evidence of a real difference in the effects of sativa and indica types.

Characteristic differences between indica and sativa cultivars can be found in the presence of aromatic compounds (terpenes) in the plant. Bedica® contains a high amount of the myrcene terpene, which is known to have a calming effect.

Bedica® contains 14% THC with less than 1% CBD.

Bedica® is available in granular form.

Terpene Profile – Bedica

Content in mg/gr


THC <1.0% | CBD 9%

Introduced in 2014, Bedrolite® is the brand name for the cultivar Cannabis sativa L. ‘Rensina’.

Cannabis sativa L. ‘Rensina’ is a so-called CBD-only product, with less than 1% THC and 9% CBD. Due to the extremely low levels of THC, it has no intoxicating properties. Bedrolite® has become the preferred choice of a number of patients with severe, intractable (untreatable) forms of epilepsy.

Bedrolite® is available in granular form.

Terpene Profile – Bedrolite

Content in mg/gr

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.

Start typing and press Enter to search

Renger Witkamp
Indica and Sativa - how the industry classifies